BIVRX vs. UPRO

In the year-to-date period, BIVRX achieves a -2.59% return, which is significantly higher than UPRO's -12.30% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

BIVRX has a 2.48% expense ratio, which is higher than UPRO's 0.92% expense ratio.

This table presents a comparison of risk-adjusted performance metrics for Invenomic Fund (BIVRX) and ProShares UltraPro S&P 500 (UPRO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BIVRX Sharpe Ratio is -0.27, which is lower than the UPRO Sharpe Ratio of 0.15. The chart below compares the historical Sharpe Ratios of BIVRX and UPRO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BIVRX's dividend yield for the trailing twelve months is around 3.64%, more than UPRO's 1.14% yield.

The maximum BIVRX drawdown since its inception was -34.31%, smaller than the maximum UPRO drawdown of -76.82%. Use the drawdown chart below to compare losses from any high point for BIVRX and UPRO. For additional features, visit the drawdowns tool.

The current volatility for Invenomic Fund (BIVRX) is 3.38%, while ProShares UltraPro S&P 500 (UPRO) has a volatility of 14.07%. This indicates that BIVRX experiences smaller price fluctuations and is considered to be less risky than UPRO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.